Cargando…

Correction: Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670933/ https://www.ncbi.nlm.nih.gov/pubmed/36384881 http://dx.doi.org/10.1136/openhrt-2022-002060corr1

Ejemplares similares

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Lipoprotein(a) in an adult sample from the Russian population: distribution and association with atherosclerotic cardiovascular diseases
por: Ezhov, Marat V., et al.
Publicado: (2021)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
por: Makris, Anastasios, et al.
Publicado: (2023)

Correction to: Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
Publicado: (2023)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
por: Tada, Hayato, et al.
Publicado: (2019)

Author Correction: Establishment and equilibrium levels of deleterious mutations in large populations
por: Viljoen, Johan W., et al.
Publicado: (2020)

Author Correction: A randomized controlled trial of Baduanjin exercise to reduce the risk of atherosclerotic cardiovascular disease in patients with prediabetes
por: Ma, Xiaojun, et al.
Publicado: (2023)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
por: Fuior, Elena Valeria, et al.
Publicado: (2023)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Correction to: State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: the reporting—a consensus document by the European Society of Cardiovascular Radiology (ESCR)
por: Saba, Luca, et al.
Publicado: (2022)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

Plasma lipoprotein (a) and tissue plasminogen activator are associated with increased risk of atherosclerotic cardiovascular disease
por: Mayyas, Fadia, et al.
Publicado: (2022)

The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients
por: Wang, Xiaoyu, et al.
Publicado: (2023)

Correction: Fanelli Kuczmarski, M.; et al. Aspects of Dietary Diversity Differ in Their Association with Atherosclerotic Cardiovascular Risk in a Racially Diverse US Adult Population. Nutrients 2019, 11, 1034
por: Fanelli Kuczmarski, Marie, et al.
Publicado: (2019)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Age‐Related Associations of Low‐Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population‐Based Cohort Study
por: Jung, Han Na, et al.
Publicado: (2022)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
por: Fonseca, Ana F, et al.
Publicado: (2023)

Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023)

Correction to: State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: standardization of scanning protocols and measurements—a consensus document by the European Society of Cardiovascular Radiology (ESCR)
por: Saba, Luca, et al.
Publicado: (2022)

Lowering Low-Density Lipoprotein Cholesterol Concentration with Plant Stanol Esters to Reduce the Risk of Atherosclerotic Cardiovascular Disease Events at a Population Level: A Critical Discussion
por: Gylling, Helena, et al.
Publicado: (2020)

Correction: Future Coastal Population Growth and Exposure to Sea-Level Rise and Coastal Flooding - A Global Assessment
Publicado: (2015)

Correction: HMGB1 Is Associated with Atherosclerotic Plaque Composition and Burden in Patients with Stable Coronary Artery Disease
Publicado: (2014)

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
por: Lampsas, Stamatios, et al.
Publicado: (2023)

Correction to: Effects of Simvastatin on Endoplasmic Reticulum Stress-Mediated Apoptosis in Atherosclerotic Calcification
Publicado: (2022)

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression
por: Kaiser, Yannick, et al.
Publicado: (2022)

Correction: fasting remnant lipoproteins can predict postprandial hyperlipidemia
por: Nagata, Tomoki, et al.
Publicado: (2014)

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease
por: Trinder, Mark, et al.
Publicado: (2020)

Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review
por: Sascău, Radu, et al.
Publicado: (2021)

Correction to: Combined Effects of Physical Activity and Air Pollution on Cardiovascular Disease: A Population‐Based Study
Publicado: (2020)

Correction to: Diabetes, cardiovascular disease and the microcirculation
por: Strain, W. David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gu66fnnc68vo8up7hb61cuuoqg